Pharma Mar SA ( (PHMMF) ) has released its Q2 earnings. Here is a breakdown of the information Pharma Mar SA presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pharma Mar SA is a biopharmaceutical company specializing in the development and commercialization of innovative oncology and RNA interference therapies, with a focus on small cell lung cancer and age-related macular degeneration treatments.
Pharma Mar SA reported a strong financial performance for the first half of 2025, with group revenue reaching €95.3 million, an 18% increase compared to the same period in 2024. The company also achieved significant milestones in its oncology segment, including regulatory advancements for its drug Zepzelca®.
Key financial metrics highlight a notable improvement, with recurring revenue increasing by 5% to €72.2 million and non-recurring revenue surging by 87% to €23.0 million. The company’s EBITDA rose to €25.1 million, a significant turnaround from a negative EBITDA in the previous year. Strategic developments include a new licensing agreement with Merck for Zepzelca in Japan and a substantial grant for RNAi research.
In the oncology sector, Pharma Mar made strides with Zepzelca®, receiving approvals and priority reviews from various regulatory bodies, including the FDA and EMA. The company is also advancing its clinical trials for other oncology and RNAi treatments, supported by increased R&D expenditure.
Looking ahead, Pharma Mar SA remains focused on expanding its market presence and advancing its clinical pipeline. The company’s management is optimistic about future growth, supported by its robust financial position and strategic partnerships.